Please login to the form below

Not currently logged in
Email:
Password:

Elan and Wyeth limit Alzheimer's trial

Irish biotech Elan and partner Wyeth have removed the highest dose of potential Alzheimer's therapy bapineuzumab from phase III trials

Irish biotech Elan and partner Wyeth have removed the highest dose of potential Alzheimer's therapy bapineuzumab from phase III trials.

The companies will discontinue trials of 2.0mg/kg of bazineuzumab in two ongoing phase III trials in patients with mild-to-moderate Alzheimer's disease (AD) who do not carry the Apolipoprotein E4 allele. However, trials of 0.5mg/kg and 1.0mg/kg will continue as planned.

The decision to discontinue the higher dose was made following a review of vasogenic edema, an accumulation of water in the brain, by the study's independent Safety Monitoring Committee (SMC).

Two further studies, testing a dose of 0.5mg/kg in patients who are carriers of the Apolipoprotein E4 allele are unaffected by this decision.

Elan president Dr Carlos Paya said: "Our review of the safety data and the feedback from the Safety Monitoring Committee made it clear that continued development of the highest dose was not advisable. The decision to remove the highest dose from development reduces risk to patients and it also helps to reduce risk to the overall development effort."

The global bapineuzumab phase III programme consists of four randomised, double-blind, placebo-controlled studies involving approximately 4,000 patients.

2nd April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....

Infographics